Our mission:
Stop & Prevent

We focus on fighting COVID-endemic illnesses and cancers.

THE PANDEMIC BROKE OUR IMMUNITY

It is now undeniable – COVID19 broke our immunity with grim consequences.

In the COVID19 endemic era, beginning 2023, we are witnessing 20% or higher excess deaths in teenagers and working adults under the age of 45, mainly from the unexpected rise in heart attacks and strokes in the young people (read).

Renal, hematological, colon, and lung cancer risks in younger people were found escalated within 3 months of COVID19 infection, with the highest risk increase (115%) seen in women (read). 5-fold increased incidences of cancer hyperprogression in the first 2 months of COVID19 infection was also reported in clinical studies (read).

Untreated and often untreatable immune disorders, now dubbed as Long COVID, are keeping millions of people, from infants to the elderly, in sickness (read)(read).

We decided to do something about it.

Our Approach

From its inception, Xylonix has focused on the immunity issues of dysfunctional macrophages. These reprogrammed macrophages enable cancers to be immune evasive, highly metastatic, and treatment resistant (read). This focus led to the development of our oncology agent C010DS-Zn (read). Early in the COVID pandemic our understanding of dysfunctional macrophages enabled us to quickly identify the close resemblance between COVID-reprogrammed macrophages (read) and cancer-associated macrophages (read), and the associated long-term health effects of COVID19, such as myocarditis, diabetes, and MIS-C (read). Since then, we have been preparing the scientific and product framework for the prevention of COVID19 and treatment of its long-term health effects (read, read).

Reduce the infection frequency of COVID19 and other viral infectious diseases.
Reduce baseline systemic inflammation.
Restore the broken macrophage immunity to fight the supercharged cancer and long COVID.

Our development DNA:

Useful. Scientific. Accessible.

Reduce the infection frequency of COVID19 and other viral infectious diseases.

Risks of deaths and hospitalizations from all cause exponentially increase after repeat infections from COVID19 (read). We developed a PVD-Iodine-based antiseptic nasal spray suitable for frequent disinfection, to help curb the re-infection risks from a broad range of pathogens, like COVID19, and to help promote the idea of nasal hygiene. It is also useful for Rhinitis - nasal allergy demands. Available now.

Our Solution

Reduce baseline systemic inflammation.

Chronic systemic exposure to inflammatory antigens contribute to systemic inflammation and aggravation leading toward autoimmune disease pathologies through endotoxemia. We developed a product for efficient removal of fecal endotoxin sources, which is a major source of inflammatory antigens in many autoimmune diseases (read). The products are also intrinsically useful for digestive health market demands. Now available, worldwide.

Restore the broken macrophage immunity to fight the supercharged cancer and long COVID.

With COVID19 becoming an endemic disease, the immune dysfunctions that drive the turbocharged cancers and long COVIDs can happen to anyone after repeat infections. While the virus cannot be stopped, we are working with collaborators at Duke-NUS to stop the cancers and long COVID by restoring the macrophage immunity that was broken by the reprogramming abilities of cancer and long COVID in the first place (read).